Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Castration-Resistant Prostate Cancer: early-phase trial registry
45 of 70 indexed Metastatic Castration-Resistant Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #198 of 28,707 conditions by registered trial count.
70 US clinical trials · 45 currently recruiting · #198 of 28,707 conditions by registered trial count
Metastatic Castration-Resistant Prostate Cancer: 70 US clinical trials tracked, 45 recruiting.
Metastatic Castration-Resistant Prostate Cancer is the subject of 70 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 60 in Phase 1-2 (earlier-stage). The most active sponsor is University of Utah, running 5 of these trials.
Enrollment posture brief
Registry condition metastatic-castration-resistant-prostate-cancer
OPEN 45 | RECR 64% | LATE 9 | EARLY 60 | RANK #198 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Cardiac Rehabilitation (64% recruiting · 14 trials)
Metastatic Castration-Resistant Prostate Cancer lists 45 open slots (64% of 70 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Castration-Resistant Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Castration-Resistant Prostate Cancer is recruiting above its size-band peers.
45 of 70 indexed trials (64.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Castration-Resistant Prostate Cancer trials is spread across many organizations.
University of Utah accounts for 5 of 70 trials (7.1%). 48 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Castration-Resistant Prostate Cancer enrolment sits around 72 participants.
Median target enrolment is 72 among the 70 trials that report a genuine target (sentinel values excluded). 41 of those (58.6%) plan for fewer than 100 participants.
-
Metastatic Castration-Resistant Prostate Cancer research is mostly interventional.
69 interventional and 1 observational studies make up this index (98.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
70 total, page 2 of 2
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Fusion Pharmaceuticals
NCT05219500
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals
NCT02123758
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
Rahul Aggarwal
NCT05011188
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
VA Office of Research and Development
NCT04104893
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
University of Utah
NCT04109729
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Dana-Farber Cancer Institute
NCT04846478
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
University of Utah
NCT04754191
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
Robert Flavell, MD, PhD
NCT05245006
Abemaciclib With or Without Atezolizumab for mCRPC
Dana-Farber Cancer Institute
NCT04751929
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Brown University
NCT04253262
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bayer
NCT02141438
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
NCT04925284
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
NCT04887506
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics
NCT02711956
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Cardiff Oncology
NCT03414034
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
NCT01942837
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Global Development
NCT01650194
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT03829436
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
University of Alabama at Birmingham
NCT02047253
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Tulane University
NCT04158245
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 33 |
| Phase 2 | 27 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Castration-Resistant Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Castration-Resistant Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Castration-Resistant Prostate Cancer page
70 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 45 Metastatic Castration-Resistant Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Utah sponsors the most Metastatic Castration-Resistant Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See University of Utah's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Castration-Resistant Prostate Cancer condition card totals 70 registered trials; most-linked intervention Enzalutamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.